Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

Experimental Hematology

Volumn 35, Issue 2, 2007, Pages 297-304

  Kokhaei, Parviz ^a   Palma, Marzia ^a   Hansson, Lotta ^a,b   Österborg, Anders ^a,b   Mellstedt, Håkan ^a,b   Choudhury, Aniruddha ^a  

^a Karolinska Krankenhaus   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RAS PROTEIN; TELOMERASE; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GENE EXPRESSION PROFILING; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE;

EID: 33846349566     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.10.006     Document Type: Article

References (39)

1. Nakamura T.M., Morin G.B., Chapman K.B., et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277 (1997) 955-959
2. Nugent C.I., and Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 12 (1998) 1073-1085
3. Collins K., and Mitchell J.R. Telomerase in the human organism. Oncogene 21 (2002) 564-579
4. Smogorzewska A., and de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J 21 (2002) 4338-4348
5. Kim N.W., Piatyszek M.A., Prowse K.R., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
6. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33 (1997) 787-791
7. Counter C.M., Botelho F.M., Wang P., Harley C.B., and Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J Virol 68 (1994) 3410-3414
8. Counter C.M., Avilion A.A., LeFeuvre C.E., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11 (1992) 1921-1929
9. Harrington L., Zhou W., McPhail T., et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 11 (1997) 3109-3115
10. Meyerson M., Counter C.M., Eaton E.N., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90 (1997) 785-795
11. Counter C.M., Gupta J., Harley C.B., Leber B., and Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85 (1995) 2315-2320
12. Ely S.A., Chadburn A., Dayton C.M., Cesarman E., and Knowles D.M. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer 89 (2000) 445-452
13. Trentin L., Ballon G., Ometto L., et al. Telomerase activity in chronic lymphoproliferative disorders of B-cell lineage. Br J Haematol 106 (1999) 662-668
14. Damle R.N., Batliwalla F.M., Ghiotto F., et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 103 (2004) 375-382
15. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
16. Kokhaei P., Choudhury A., Mahdian R., et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 18 (2004) 1810-1815
17. Lefranc M.P., Giudicelli V., Ginestoux C., et al. IMGT, the International ImMunoGeneTics database. Nucleic Acids Res 27 (1999) 209-212
18. Brunsvig P.F., Aamdal S., Gjertsen M.K., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55 (2006) 1553-1564
19. Kokhaei P., Rezvany M.R., Virving L., et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 17 (2003) 894-899
20. Spisek R., Bretaudeau L., Barbieux I., Meflah K., and Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 50 (2001) 417-427
21. Fischer K., and Mackensen A. The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods 31 (2003) 135-142
22. Tchirkov A., Chaleteix C., Magnac C., et al. hTERT expression and prognosis in B-chronic lymphocytic leukemia. Ann Oncol 15 (2004) 1476-1480
23. Verstovsek S., Giles F.J., O'Brien S., et al. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res 28 (2004) 707-711
24. Hultdin M., Rosenquist R., Thunberg U., et al. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. Br J Cancer 88 (2003) 593-598
25. Grabowski P., Hultdin M., Karlsson K., et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 105 (2005) 4807-4812
26. Norrback K.F., and Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 33 (1997) 774-780
27. Nowak J., Januszkiewicz D., Lewandowski K., et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol 15 (2003) 75-80
28. Arai J., Yasukawa M., Ohminami H., et al. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97 (2001) 2903-2907
29. Minev B., Hipp J., Firat H., et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 97 (2000) 4796-4801
30. Tajima K., Ito Y., Demachi A., et al. Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. Int J Cancer 110 (2004) 403-412
31. Vonderheide R.H., Domchek S.M., Schultze J.L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10 (2004) 828-839
32. Parkhurst M.R., Riley J.P., Igarashi T., et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10 (2004) 4688-4698
33. Gaudernack G, Buanes T, Meo M, et al. Clinical trials of a peptide based vaccine targeting telomerase [abstract]. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 2003;Abstract 666.
34. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 23 (2005) 413-419
35. Shay J.W., and Wright W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2 (2002) 257-265
36. Spaner D.E., Hammond C., Mena J., Foden C., and Deabreu A. A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunol Immunother 54 (2005) 635-646
37. Hus I., Rolinski J., Tabarkiewicz J., et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19 (2005) 1621-1627
38. Rezvany M.R., Jeddi-Tehrani M., Rabbani H., et al. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 111 (2000) 230-238
39. Ruffini P.A., Neelapu S.S., Kwak L.W., and Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 87 (2002) 989-1001